Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 3.1300 |
| Open | 3.2900 |
| Bid | 3.1600 x 21500 |
| Ask | 3.1500 x 2900 |
| Day's Range | 2.9500 - 3.3000 |
| 52 Week Range | 2.0900 - 15.8640 |
| Volume | |
| Avg. Volume | 23,095,638 |
| Market Cap | 5.579B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.6720 |
| Earnings Date | Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.41 |
- Simply Wall St.
Is Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Trading At A 33% Discount?
Today we will run through one way of estimating the intrinsic value of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) by...
- Simply Wall St.
How Much Of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Do Insiders Own?
A look at the shareholders of Ginkgo Bioworks Holdings, Inc. ( NYSE:DNA ) can tell us which group is most powerful...
- GlobeNewswire
Cronos Group and Ginkgo Bioworks Announce Achievement of THCV Equity Milestone
TORONTO and BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos"), an innovative global cannabinoid company, and Ginkgo Bioworks (NYSE: DNA) (“Ginkgo”), the leading horizontal platform for cell programming, today announced the achievement of the third target productivity milestone in their partnership to produce eight cultured cannabinoids. Using Ginkgo’s platform for organism design and development, Cronos has successfully achieved the productivity ta
© 2022 Yahoo. All rights reserved.
